Melanoma (Skin)Phase 3NCT00003641
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
A Phase 3 study testing interferon alfa-2b and observation in people with Melanoma (Skin), run by ECOG-ACRIN Cancer Research Group at 533 sites in 4 countries.
Trial summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Melanoma (Skin)
- What is being tested?
- interferon alfa-2b and observation
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,150 participants
- Where
- 533 sitesin 4 countries
- Study dates
- 25 Mar 1999to 26 May 2026
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically confirmed primary melanoma of cutaneous origin
- Stage II (T3 N0 M0 1.5-4.0 mm Breslow depth)
- Clinically negative regional lymph node pathologic status unknown OR
- Histologically negative regional lymph nodes
- Stage III (T4 N0 M0)
- Greater than 4.0 mm Breslow depth OR
Show all 34Show fewer
- Stage III (T1-4 N1)
- One lymph node positive microscopically
- Patients must meet at least 1 of the following criteria:
- T2b N0 - primary melanoma 1.01-2.0 mm with ulceration, node negative
- T3a-b N0 - primary melanoma 2.01-4.0 mm with and without ulceration, node negative
- T4a-b N0 - primary melanoma > 4.0 mm with or without ulceration, node negative
- T1a N1a-2a (microscopic) - primary melanoma of any thickness with microscopically positive lymph node (any number)
- Patients with a positive sentinel node should undergo complete lymphadenectomy of the nodal basin prior to study
- Must complete all primary therapy (wide excision with or without lymphadenectomy) and be randomized in this study within 84 days of wide excision
- Must have undergone an adequate wide excision of the primary lesion
- Age 18 and over (For ECOG patients only, patients must be >=10 years)
- Eastern Cooperative Oncology Group (ECOG) Performance status of 0-1
- Adequate hematopoietic, hepatic, and renal function based on the following tests:
- White blood cell (WBC) cout at least 3,000/mm^3
- Platelet count at least 125,000/mm^3
- Hematocrit at least 30%
- Bilirubin no greater than 2 times upper limit of normal (ULN)
- Aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and alkaline phosphatase no greater than 2 times ULN
- If lactate dehydrogenase or alkaline phosphatase is above normal, a contrast-enhanced computed tomography (CT) scan or Magnetic resonance imaging (MRI) of the liver is required to document the absence of tumor
- Blood urea nitrogen (BUN) no greater than 33 mg/dL OR Creatinine no greater than 1.8 mg/dL
- No other concurrent or prior malignancies within the past 5 years except:
- Cancer in situ
- Lobular carcinoma in situ of the breast
- Carcinoma in situ of the cervix
- Atypical melanocytic hyperplasia or Clark 1 melanoma in situ
- Basal or squamous cell skin cancer
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 6 months after study
Who cannot join
- Clinical, radiological/laboratory, or pathological evidence of incompletely resected melanoma or any distant metastatic disease
- Clinically palpable lymphadenopathy
- Evidence of organic brain syndrome or significant impairment of basal cognitive function or any psychiatric disorder that would preclude study participation
- Other significant medical or surgical condition, or any medication or treatment regimens, that would interfere with study participation
- Pregnant or nursing
- Other history of invasive melanoma
Show all 15Show fewer
- Autoimmune disorders or conditions of immunosuppression
- History of active ischemic heart disease
- Cerebrovascular disease
- Congestive heart failure (New York Heart Association class III or IV heart disease)
- Prior or concurrent chemotherapy
- Prior immunotherapy including tumor vaccines, interferon, interleukins, levamisole, or other biologic response modifiers for melanoma
- Concurrent systemic corticosteroids including oral steroids (i.e., prednisone, dexamethasone), topical steroid creams or ointments, or any steroid-containing inhalers
- Prior or concurrent radiotherapy
- Other concurrent immunosuppressive medications
Trial locations and contacts
533 sites in 4 countries.
322 sites in 4 countries
United States300 sites
Hickman Cancer Center at Bixby Medical Center
Adrian, Michigan, 49221
Akron Children's Hospital
Akron, Ohio, 44308-1062
Summa Center for Cancer Care at Akron City Hospital
Akron, Ohio, 44309-2090
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87131-5636
Tulane Cancer Center Office of Clinical Research
Alexandria, Louisiana, 71315-3198
Study site
Alexandria, Minnesota, 56308
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
Allentown, Pennsylvania, 18105
Harrington Cancer Center
Amarillo, Texas, 79106
American Fork Hospital
American Fork, Utah, 84003
McFarland Clinic, PC
Ames, Iowa, 50010
Saint Joseph Mercy Cancer Center
Ann Arbor, Michigan, 48106-0995
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
DeCesaris Cancer Institute at Anne Arundel Medical Center
Annapolis, Maryland, 21401
Hospital District Sixth of Harper County
Anthony, Kansas, 67003
Kaiser Permanente - Deer Valley
Antioch, California, 94531
Fox Valley Hematology and Oncology - East Grant Street
Appleton, Wisconsin, 54911-3496
Randolph Hospital
Asheboro, North Carolina, 27203-5400
Cancer Care at Our Lady of Bellefonte Hospital
Ashland, Kentucky, 41101
Piedmont Hospital
Atlanta, Georgia, 30309
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus
Atlanta, Georgia, 30322
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322
Northside Hospital Cancer Center
Atlanta, Georgia, 30342-1611
Saint Joseph's Hospital of Atlanta
Atlanta, Georgia, 30342-1701
CCOP - Atlanta Regional
Atlanta, Georgia, 30342
MBCCOP - Medical College of Georgia Cancer Center
Augusta, Georgia, 30912
Aurora Presbyterian Hospital
Aurora, Colorado, 80012
Rush-Copley Cancer Care Center
Aurora, Illinois, 60504
WellStar Cobb Hospital
Austell, Georgia, 30106
Greater Baltimore Medical Center Cancer Center
Baltimore, Maryland, 21204
Barberton Citizens Hospital
Barberton, Ohio, 44203
Ochsner Health Center - Bluebonnet
Baton Rouge, Louisiana, 70809
St. Francis Hospital and Health Centers - Beech Grove Campus
Beech Grove, Indiana, 46107
Mary Rutan Hospital
Bellefontaine, Ohio, 43311
St. Joseph Cancer Center
Bellingham, Washington, 98225
MeritCare Bemidji
Bemidji, Minnesota, 56601
Alta Bates Summit Comprehensive Cancer Center
Berkeley, California, 94704
Hematology Oncology Associates of Illinois - Berwyn
Berwyn, Illinois, 60402
St. Luke's Cancer Network at St. Luke's Hospital
Bethlehem, Pennsylvania, 18015
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
Billings Clinic - Downtown
Billings, Montana, 59107-7000
UAB Comprehensive Cancer Center
Birmingham, Alabama, 35294
Tufts-NEMC Cancer Center
Boston, Massachusetts, 02111
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Boulder Community Hospital
Boulder, Colorado, 80301-9019
Wood County Oncology Center
Bowling Green, Ohio, 43402
Bozeman Deaconess Cancer Center
Bozeman, Montana, 59715
Olympic Hematology and Oncology
Bremerton, Washington, 98310
Peninsula Medical Center
Burlingame, California, 94010
Aurora Memorial Hospital of Burlington
Burlington, Wisconsin, 53105
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
St. James Healthcare Cancer Care
Butte, Montana, 59701
Mercy Cancer Center at Mercy Medical Center
Canton, Ohio, 44708
Aultman Cancer Center at Aultman Hospital
Canton, Ohio, 44710-1799
Rocky Mountain Oncology
Casper, Wyoming, 82609
Sandra L. Maxwell Cancer Center
Cedar City, Utah, 84720
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Mercy Regional Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Providence Centralia Hospital
Centralia, Washington, 98531-9027
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
West Virginia University Health Sciences Center - Charleston
Charleston, West Virginia, 25302
Blumenthal Cancer Center at Carolinas Medical Center
Charlotte, North Carolina, 28232-2861
Presbyterian Cancer Center at Presbyterian Hospital
Charlotte, North Carolina, 28233-3549
University of Virginia Cancer Center
Charlottesville, Virginia, 22908
Saint Luke's Hospital
Chesterfield, Missouri, 63017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, 60611-3013
Hematology and Oncology Associates
Chicago, Illinois, 60611
Saint Joseph Hospital
Chicago, Illinois, 60657
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Marshfield Clinic - Chippewa Center
Chippewa Falls, Wisconsin, 54729
Christ Hospital Cancer Center
Cincinnati, Ohio, 45219
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, 45267
Case Comprehensive Cancer Center
Cleveland, Ohio, 44106-5065
MetroHealth Cancer Care Center at MetroHealth Medical Center
Cleveland, Ohio, 44109
Medical Oncology and Hematology Associates - West Des Moines
Clive, Iowa, 50325
North Coast Cancer Care - Clyde
Clyde, Ohio, 43410
Penrose Cancer Center at Penrose Hospital
Colorado Springs, Colorado, 80933
Ellis Fischel Cancer Center at University of Missouri - Columbia
Columbia, Missouri, 65203
John B. Amos Cancer Center
Columbus, Georgia, 31904
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210-1240
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
CCOP - Columbus
Columbus, Ohio, 43215
Grant Medical Center Cancer Care
Columbus, Ohio, 43215
Mount Carmel Health - West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Mercy and Unity Cancer Center at Mercy Hospital
Coon Rapids, Minnesota, 55433
Medical City Dallas Hospital
Dallas, Texas, 75230
Praxair Cancer Center at Danbury Hospital
Danbury, Connecticut, 06810
Geisinger Cancer Institute at Geisinger Health
Danville, Pennsylvania, 17822-0001
Danville Regional Medical Center
Danville, Virginia, 24541
Genesis Regional Cancer Center at Genesis Medical Center
Davenport, Iowa, 52803
Genesis Medical Center - West Campus
Davenport, Iowa, 52804
Dayton Children's - Dayton
Dayton, Ohio, 45404
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
David L. Rike Cancer Center at Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
CCOP - Dayton
Dayton, Ohio, 45420
Herbert D. Kerman Regional Oncology Center - Daytona Beach
Daytona Beach, Florida, 32114
Oakwood Cancer Center at Oakwood Hospital and Medical Center
Dearborn, Michigan, 48123-2500
Charles B. Eberhart Cancer Center at DeKalb Medical Center
Decatur, Georgia, 30033
Veterans Affairs Medical Center - Atlanta (Decatur)
Decatur, Georgia, 30033
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526
Grady Memorial Hospital
Delaware, Ohio, 43015
St. Anthony Central Hospital
Denver, Colorado, 80204
Kaiser Permanente - Denver
Denver, Colorado, 80205
Porter Adventist Hospital
Denver, Colorado, 80210
Presbyterian - St. Luke's Medical Center
Denver, Colorado, 80218
St. Joseph Hospital
Denver, Colorado, 80218
Rose Medical Center
Denver, Colorado, 80220
CCOP - Colorado Cancer Research Program
Denver, Colorado, 80224-2522
Mercy Capitol Hospital
Des Moines, Iowa, 50307
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa, 50314
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
John Stoddard Cancer Center at Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Southern California Permanente Medical Group
Downey, California, 90027
Duluth Clinic Cancer Center - Duluth
Duluth, Minnesota, 55805-1983
CCOP - Duluth
Duluth, Minnesota, 55805
Miller - Dwan Medical Center
Duluth, Minnesota, 55805
St. Luke's Hospital Cancer Care Center
Duluth, Minnesota, 55805
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
CCOP - Hematology-Oncology Associates of Central New York
East Syracuse, New York, 13057
Center for Cancer Treatment & Prevention at Sacred Heart Hospital
Eau Claire, Wisconsin, 54701
Marshfield Clinic Cancer Care at Regional Cancer Center
Eau Claire, Wisconsin, 54701
Fairview Southdale Hospital
Edina, Minnesota, 55435
Crossroads Cancer Center
Effingham, Illinois, 62401
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Elkhart Clinic, LLC
Elkhart, Indiana, 46514-2098
Michiana Hematology-Oncology, PC - Elkhart
Elkhart, Indiana, 46514
Elkhart General Hospital
Elkhart, Indiana, 46515
Vince Lombardi Cancer Center at Aurora Lakeland Medical Center - Elkhorn
Elkhorn, Wisconsin, 53121
Union Hospital Cancer Program at Union Hospital
Elkton, Maryland, 21921
Community Cancer Center
Elyria, Ohio, 44035
Hematology Oncology Center
Elyria, Ohio, 44035
Swedish Medical Center
Englewood, Colorado, 80110
Green Bay Oncology, Limited - Escanaba
Escanaba, Michigan, 49431
Evanston Hospital
Evanston, Illinois, 60201-1781
CCOP - MeritCare Hospital
Fargo, North Dakota, 58122
MeritCare Broadway
Fargo, North Dakota, 58122
St. Francis Hospital
Federal Way, Washington, 98003
Fergus Falls Medical Group, PA
Fergus Falls, Minnesota, 56537
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Hunterdon Regional Cancer Center at Hunterdon Medical Center
Flemington, New Jersey, 08822
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
Fort Smith, Arkansas, 72903
Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Oncology Alliance - Franklin
Franklin, Wisconsin, 53132
Fredericksburg Oncology, Incorporated
Fredericksburg, Virginia, 22401
Kaiser Permanente - Fremont
Fremont, California, 94538
Mercy and Unity Cancer Center at Unity Hospital
Fridley, Minnesota, 55432
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
Oncology Alliance, SC - Milwaukee - East
Glendale, Wisconsin, 53212-1038
Charles R. Wood Cancer Center at Glens Falls Hospital
Glens Falls, New York, 12801
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
Saint Francis Cancer Treatment Center at Saint Francis Memorial Health Center
Grand Island, Nebraska, 68803
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
Grand Junction, Colorado, 81502
Big Sky Oncology
Great Falls, Montana, 59405-5309
Great Falls Clinic - Main Facility
Great Falls, Montana, 59405
Sletten Cancer Institute at Benefis Healthcare
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54301-3526
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
St. Mary's Hospital Medical Center - Green Bay
Green Bay, Wisconsin, 54303
St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54307-3508
Vince Lombardi Cancer Clinic - Green Bay at Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311
Marin Cancer Institute at Marin General Hospital
Greenbrae, California, 94904
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
Greensboro, North Carolina, 27403-1198
Leo W. Jenkins Cancer Center at ECU Medical School
Greenville, North Carolina, 27834
Wayne Hospital
Greenville, Ohio, 45331
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030
Van Elslander Cancer Center at St. John Hospital and Medical Center
Grosse Pointe Woods, Michigan, 48236
CCOP - Northern New Jersey
Hackensack, New Jersey, 07601
Hackensack University Medical Center Cancer Center
Hackensack, New Jersey, 07601
Cancer Institute of New Jersey at Hamilton
Hamilton, New Jersey, 08690
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
Hartford, Connecticut, 06105
Ingalls Cancer Care Center at Ingalls Memorial Hospital
Harvey, Illinois, 60426
Northern Montana Hospital
Havre, Montana, 59501
Kaiser Permanente Medical Center - Hayward
Hayward, California, 94545
Geisinger Hazleton Cancer Center
Hazleton, Pennsylvania, 18201
St. Peter's Hospital
Helena, Montana, 59601
Penn State Children's Hospital
Hershey, Pennsylvania, 17033-0850
Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
Kellogg Cancer Care Center
Highland Park, Illinois, 60035
Hinsdale Hematology Oncology Associates
Hinsdale, Illinois, 60521
Kaiser Permanente - Moanalua Medical Center and Clinic
Honolulu, Hawaii, 96819
Edwards Comprehensive Cancer Center at Cabell Huntington Hospital
Huntington, West Virginia, 25701
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202-5289
William N. Wishard Memorial Hospital
Indianapolis, Indiana, 46202
Dickinson County Healthcare System
Iron Mountain, Michigan, 49801
Foote Memorial Hospital
Jackson, Michigan, 49201
University of Mississippi Cancer Clinic
Jackson, Mississippi, 39216-4505
Baptist Cancer Institute - Jacksonville
Jacksonville, Florida, 32207
UW Cancer Center Johnson Creek
Johnson Creek, Wisconsin, 53038
Midwest Center for Hematology/Oncology
Joliet, Illinois, 60432
Ella Milbank Foshay Cancer Center at Jupiter Medical Center
Jupiter, Florida, 33458
Borgess Medical Center
Kalamazoo, Michigan, 49001
West Michigan Cancer Center
Kalamazoo, Michigan, 49007-3731
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Glacier Oncology, PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology at KRMC
Kalispell, Montana, 59901
Children's Mercy Hospital
Kansas City, Missouri, 64108
Truman Medical Center - Hospital Hill
Kansas City, Missouri, 64108
Saint Luke's Cancer Institute at Saint Luke's Hospital
Kansas City, Missouri, 64111
St. Joseph Medical Center
Kansas City, Missouri, 64114
North Kansas City Hospital
Kansas City, Missouri, 64116
Heartland Hematology Oncology Associates, Incorporated
Kansas City, Missouri, 64118
CCOP - Kansas City
Kansas City, Missouri, 64131
Research Medical Center
Kansas City, Missouri, 64132
Columbia Basin Hematology
Kennewick, Washington, 99336
Oncology Alliance - Kenosha South
Kenosha, Wisconsin, 53143
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center
Kingsport, Tennessee, 37662
East Tennessee Children's Hospital
Knoxville, Tennessee, 37901
Center for Biomedical Research
Knoxville, Tennessee, 37909
Howard Community Hospital
Kokomo, Indiana, 46904
Gundersen Lutheran Center for Cancer and Blood
La Crosse, Wisconsin, 54601
Center for Cancer Therapy at LaPorte Hospital and Health Services
La Porte, Indiana, 46350
Michiana Hematology Oncology PC - La Porte
La Porte, Indiana, 46350
Kaiser Permanente - Lafayette
Lafayette, Colorado, 80026
Monter Cancer Center of the North Shore-LIJ Health System
Lake Success, New York, 11042
Lakeland Regional Cancer Center at Lakeland Regional Medical Center
Lakeland, Florida, 33805
Haematology-Oncology Associates of Ohio and Michigan, PC
Lambertville, Michigan, 48144
Fairfield Medical Center
Lancaster, Ohio, 43130
Lancaster General Hospital
Lancaster, Pennsylvania, 17604
Sparrow Regional Cancer Center
Lansing, Michigan, 48912-1811
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Gwinnett Medical Center
Lawrenceville, Georgia, 30045
Cleo Craig Cancer Research Clinic
Lawton, Oklahoma, 73505
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756-0002
Saint Luke's East - Lee's Summit
Lee's Summit, Missouri, 64086
Tunnell Cancer Center at Beebe Medical Center
Lewes, Delaware, 19958
Lewistown Hospital
Lewistown, Pennsylvania, 17044
Cancer Center of Kansas, PA - Liberal
Liberal, Kansas, 67905
Liberty Hospital
Liberty, Missouri, 64068
North Shore Oncology and Hematology Associates, Limited - Libertyville
Libertyville, Illinois, 60048
St. Rita's Medical Center
Lima, Ohio, 45801
Lima Memorial Hospital
Lima, Ohio, 45804
Cancer Resource Center - Lincoln
Lincoln, Nebraska, 68510
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
St. Mary Mercy Hospital
Livonia, Michigan, 48154
Logan Regional Hospital
Logan, Utah, 84321
Loma Linda University Cancer Institute at Loma Linda University Medical Center
Loma Linda, California, 92354
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Hope Cancer Care Center at Longmont United Hospital
Longmont, Colorado, 80501
Drs. Carrol, Sheth, Raghavan
Louisville, Kentucky, 40215
McKee Medical Center
Loveland, Colorado, 80539
Dean Medical Center - Madison
Madison, Wisconsin, 53717
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
Madison, Wisconsin, 53792-6164
Norris Cotton Cancer Center at Catholic Medical Center
Manchester, New Hampshire, 03102
CCOP - North Shore University Hospital
Manhasset, New York, 11030
Don Monti Comprehensive Cancer Center at North Shore University Hospital
Manhasset, New York, 11030
Holy Family Memorial Medical Center Cancer Care Center
Manitowoc, Wisconsin, 54221-1450
HealthEast Cancer Care at St. John's Hospital
Maplewood, Minnesota, 55109
Minnesota Oncology Hematology, PA - Maplewood
Maplewood, Minnesota, 55109
Kennestone Cancer Center at Wellstar Kennestone Hospital
Marietta, Georgia, 30060
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Bay Area Cancer Care Center at Bay Area Medical Center
Marinette, Wisconsin, 54143
Vince Lombardi Cancer Clinic - Marinette
Marinette, Wisconsin, 54143
Marshfield Clinic - Marshfield Center
Marshfield, Wisconsin, 54449
Saint Joseph's Hospital
Marshfield, Wisconsin, 54449
Northwest Ohio Oncology Center
Maumee, Ohio, 43537-1839
St. Luke's Hospital
Maumee, Ohio, 43537
Aurora Advanced Healthcare East Mequon Clinic
Mequon, Wisconsin, 53092
University of Miami Sylvester Comprehensive Cancer Center - Miami
Miami, Florida, 33136
CCOP - Mount Sinai Medical Center
Miami Beach, Florida, 33140
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Medical Consultants, Limited
Milwaukee, Wisconsin, 53215
Oncology Alliance, SC - Milwaukee - South
Milwaukee, Wisconsin, 53215
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, 53226
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Marshfield Clinic - Lakeland Center
Minocqua, Wisconsin, 54548
Michiana Hematology-Oncology, PC - South Bend
Mishawaka, Indiana, 46545-1470
Saint Joseph Regional Medical Center
Mishawaka, Indiana, 46545-1470
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59807-7877
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59807
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, 36688
Louisiana State University Health Sciences Center - Monroe
Monroe, Louisiana, 71210
Community Cancer Center of Monroe
Monroe, Michigan, 48162
Mercy Memorial Hospital - Monroe
Monroe, Michigan, 48162
Mary Babb Randolph Cancer Center at West Virginia University Hospitals
Morgantown, West Virginia, 26506
Knox Community Hospital
Mount Vernon, Ohio, 43050
Skagit Valley Hospital Cancer Care Center
Mount Vernon, Washington, 98273
Cancer Center at Ball Memorial Hospital
Muncie, Indiana, 47303-3499
Medical Consultants, PC at Ball Memorial Cancer Center
Muncie, Indiana, 47303
Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
Murray, Utah, 84157
Canada20 sites
Royal Victoria Hospital of Barrie
Barrie, Ontario, L4M 6M2
Cross Cancer Institute at University of Alberta
Edmonton, Alberta, T6G 1Z2
Nova Scotia Cancer Centre
Halifax, Nova Scotia, B3H 1V7
Margaret and Charles Juravinski Cancer Centre
Hamilton, Ontario, L8V 5C2
British Columbia Cancer Agency - Centre for the Southern Interior
Kelowna, British Columbia, V1Y 5L3
London Regional Cancer Program at London Health Sciences Centre
London, Ontario, N6A 4L6
Hopital Notre-Dame du CHUM
Montreal, Quebec, H2L 4M1
McGill Cancer Centre at McGill University
Montreal, Quebec, H2W 1S6
CHUM - Hotel Dieu Hospital
Montreal, Quebec, H2W 1T8
R. S. McLaughlin Durham Regional Cancer Centre at Lakeridge Health Oshawa
Oshawa, Ontario, L1G 2B9
Allan Blair Cancer Centre at Pasqua Hospital
Regina, Saskatchewan, S4T 7T1
St. Catharines General Hospital at Niagara Health System
St. Catharines, Ontario, L2R 7C6
BCCA - Fraser Valley Cancer Centre
Surrey, British Columbia, V3V 1Z2
Edmond Odette Cancer Centre at Sunnybrook
Toronto, Ontario, M4N 3M5
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
Trillium Health Centre - Mississauga Site
Toronto, Ontario, M9C 1A5
British Columbia Cancer Agency - Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6
British Columbia Cancer Agency - Vancouver Island Centre
Victoria, British Columbia, V8R 6V5
Windsor Regional Cancer Centre at Windsor Regional Hospital
Windsor, Ontario, N8W 2X3
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9
Australia1 site
Westmead Institute for Cancer Research at Westmead Hospital
Westmead, New South Wales, 2145
About this study
Official title: Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically.
PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.
Read the detailed description
OBJECTIVES:
Primary Objective:
- Compare the effect of high-dose interferon alfa-2b treatment on the relapse-free survival of patients with stage II or III resected malignant melanoma.
Secondary Objectives:
- Compare the effect of this treatment regimen on overall survival of these patients.
- Assess the toxicity of this treatment in these patients.
- Compare the effect of treatment on quality of life.
OUTLINE: This is a randomized study. Patients are stratified by pathologic lymph node status (known vs unknown),lymph node staging procedures(sentinel lymph node procedure vs. elective lymph node dissection vs. no lymphadenectomy), Breslow depth (<= 1.0 mm vs. 1.01-2.0 mm vs. 2.01-4.0 mm vs > 4.0 mm), ulceration of the primary lesion (yes vs. no vs. unknown), and disease stage (lymph node positive [N1, N2a] vs. lymph node negative [N0]). Patients are randomized into one of two treatment arms in a 1:1 ratio.
- Arm I (observation): Patients undergo observation for 4 weeks.
- Arm II (Interferon Alfa-2b): Patients receive high-dose interferon alfa-2b intravenously (IV) over 20 minutes daily for 5 consecutive days. Treatment repeats weekly for 4 weeks in the absence of unacceptable toxicity.
Quality of life is assessed before treatment, at day 22, every 3 months for 2 years, and then every 6 months for 3 years.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter until 15 years after randomization.
PROJECTED ACCRUAL: A total of 1,420 patients will be accrued for this study over 5 years.
- Conditions
- Melanoma (Skin)
- Being tested
- interferon alfa-2b, observation
- Keywords
- stage II melanoma, stage III melanoma
- Medical subject headings
- Melanoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
interferon alfa-2bBiological
Also called recombinant interferon alfa, Intron-A, IFN-α 2b, NSC # 377523
Given IV
observationOther
Also called clinical observation
Patients undergo observation for 4 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Observation | Other | Patients undergo observation for 4 weeks. Receives: Other: observation |
| Interferon Alfa-2b | Experimental | Patients receive high-dose interferon alfa-2b IV over 20 minutes daily for 5 consecutive days. Treatment repeats weekly for 4 weeks in the absence of unacceptable toxicity. Receives: Biological: interferon alfa-2b |
What is being measured
The primary outcome is the main question the study is designed to answer.
5-year Relapse-free Survival Rate
Relapse-free survival (RFS) was defined as time from randomization to disease relapse or death from any cause, whichever occurred first. Patients without disease relapse were censored at last disease assessment date known of free of relapse. Kaplan-Meier method was used to estimate 5-year RFS rate in the intent-to-treat (ITT) patients.
Measured: assessed every 3 months for 2 years, every 6 months for 3 years
Secondary outcomes (1)
5-year Overall Survival Rate
Overall survival (OS) was defined as time from randomization to death from any cause. Patients still alive were censored at last known alive date. Kaplan-Meier method was used to estimate 5-year OS rate in the ITT patients.
Measured: assessed every 3 months for 2 years, every 6 months for 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2003 (estimated)
- Study start25 Mar 1999
- Primary completionJan 2015
- Study completion26 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Melanoma (Skin)Studies of the same condition, open and under way.
- More trials run by ECOG-ACRIN Cancer Research GroupThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,150 participants (actual)
Sponsor and investigators
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI), SWOG Cancer Research Network, Cancer and Leukemia Group B, NCIC Clinical Trials Group, Children's Oncology Group
- Responsible party
- Sponsor
- Investigators
- Sanjiv S. Agarwala, MD, Study chair, St. Luke's Cancer Network at St. Luke's HospitalJohn M. Kirkwood, MD, Study chair, UPMC Cancer Center at UPMC PresbyterianLawrence E. Flaherty, MD, Study chair, Barbara Ann Karmanos Cancer InstituteWilliam E. Carson, MD, Study chair, Ohio State University Comprehensive Cancer CenterMichael Smylie, MD, MB, ChB, Study chair, Cross Cancer Institute at University of AlbertaAlberto S. Pappo, MD, Principal investigator, Texas Children's Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00003641
- Sponsor's protocol ID
- E1697
- Other IDs
- E1697, U10CA023318, CDR0000066727
- Status last verified
- Sep 2026
- First submitted
- 1 Nov 1999
- Last updated
- 29 Sep 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Individual data sharing
- Yes: Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy
Study at a glance
From the registry record, last updated by the sponsor on 29 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
- ClinicalTrials.gov ID
- NCT00003641
- Acronym / sponsor ID
- E1697
- Conditions
- Melanoma (Skin)
- Keywords
- stage II melanoma, stage III melanoma
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,150 participants (actual)
- Lead sponsor
- ECOG-ACRIN Cancer Research GroupResearch network
- Collaborators
- National Cancer Institute (NCI), SWOG Cancer Research Network, Cancer and Leukemia Group B, NCIC Clinical Trials Group, Children's Oncology Group
- Study start
- 25 Mar 1999 (actual)
- Primary completion
- Jan 2015 (actual)
- Study completion
- 26 May 2026 (actual)
- First posted
- 27 Jan 2003 (estimated)
- Results
- Posted 4 May 2016
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically.
PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.
Detailed description
OBJECTIVES:
Primary Objective:
- Compare the effect of high-dose interferon alfa-2b treatment on the relapse-free survival of patients with stage II or III resected malignant melanoma.
Secondary Objectives:
- Compare the effect of this treatment regimen on overall survival of these patients.
- Assess the toxicity of this treatment in these patients.
- Compare the effect of treatment on quality of life.
OUTLINE: This is a randomized study. Patients are stratified by pathologic lymph node status (known vs unknown),lymph node staging procedures(sentinel lymph node procedure vs. elective lymph node dissection vs. no lymphadenectomy), Breslow depth (<= 1.0 mm vs. 1.01-2.0 mm vs. 2.01-4.0 mm vs > 4.0 mm), ulceration of the primary lesion (yes vs. no vs. unknown), and disease stage (lymph node positive [N1, N2a] vs. lymph node negative [N0]). Patients are randomized into one of two treatment arms in a 1:1 ratio.
- Arm I (observation): Patients undergo observation for 4 weeks.
- Arm II (Interferon Alfa-2b): Patients receive high-dose interferon alfa-2b intravenously (IV) over 20 minutes daily for 5 consecutive days. Treatment repeats weekly for 4 weeks in the absence of unacceptable toxicity.
Quality of life is assessed before treatment, at day 22, every 3 months for 2 years, and then every 6 months for 3 years.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter until 15 years after randomization.
PROJECTED ACCRUAL: A total of 1,420 patients will be accrued for this study over 5 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Observation | Other | Other: observationPatients undergo observation for 4 weeks. |
| Interferon Alfa-2b | Experimental | Biological: interferon alfa-2bPatients receive high-dose interferon alfa-2b IV over 20 minutes daily for 5 consecutive days. Treatment repeats weekly for 4 weeks in the absence of unacceptable toxicity. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (34 listed)
- Histologically confirmed primary melanoma of cutaneous origin
- Patients must meet at least 1 of the following criteria:
- Patients with a positive sentinel node should undergo complete lymphadenectomy of the nodal basin prior to study
- Must complete all primary therapy (wide excision with or without lymphadenectomy) and be randomized in this study within 84 days of wide excision
- Must have undergone an adequate wide excision of the primary lesion
Key exclusion criteria (15 listed)
- Clinical, radiological/laboratory, or pathological evidence of incompletely resected melanoma or any distant metastatic disease
- Clinically palpable lymphadenopathy
- Evidence of organic brain syndrome or significant impairment of basal cognitive function or any psychiatric disorder that would preclude study participation
- Other significant medical or surgical condition, or any medication or treatment regimens, that would interfere with study participation
- Pregnant or nursing
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| interferon alfa-2bAlso: recombinant interferon alfa, Intron-A, IFN-α 2b, NSC # 377523Given IV | Biological | Interferon Alfa-2b |
| observationAlso: clinical observationPatients undergo observation for 4 weeks. | Other | Observation |
Primary outcome
5-year Relapse-free Survival Rate
Time frame: assessed every 3 months for 2 years, every 6 months for 3 years
Relapse-free survival (RFS) was defined as time from randomization to disease relapse or death from any cause, whichever occurred first. Patients without disease relapse were censored at last disease assessment date known of free of relapse. Kaplan-Meier method was used to estimate 5-year RFS rate in the intent-to-treat (ITT) patients.
1 secondary outcome
5-year Overall Survival Rate
Time frame: assessed every 3 months for 2 years, every 6 months for 3 years
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: Yes. Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy
Related trials for Melanoma (Skin)
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
Metastatic Melanoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 1
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
Melanoma
Active, not recruitingPhase 1/2
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
Melanoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sanjiv S. Agarwala, MD study chair
St. Luke's Cancer Network at St. Luke's Hospital
John M. Kirkwood, MD study chair
UPMC Cancer Center at UPMC Presbyterian
Lawrence E. Flaherty, MD study chair
Barbara Ann Karmanos Cancer Institute
533 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing interferon alfa-2b and observation in people with Melanoma (Skin), run by ECOG-ACRIN Cancer Research Group at 533 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 34 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 533 sites in United States, Canada, Australia, South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 4 May 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
5-year Relapse-free Survival Rate (time frame: assessed every 3 months for 2 years, every 6 months for 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2026.